On the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significance
Nature Communications Open Access 04 February 2023
-
Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique
Diagnostic Pathology Open Access 30 July 2015
-
Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
BMC Cancer Open Access 23 April 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).
Saltz, L. B. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201–1208 (2004).
Jonker, D. J. et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357, 2040–2048 (2007).
De Roock, W. et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19, 508–515 (2008).
Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008).
Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626–1634 (2008).
Bokemeyer, C. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663–671 (2009).
Van Cutsem, E. et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [Abstract]. Proc. Am. Soc. Clin. Oncol. 26, 2 (2008).
Etienne-Grimaldi, M. C. et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin. Cancer Res. 14, 4830–4835 (2008).
Di Nicolantonio, F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705–5712 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P. Laurent-Puig is a Consultant and receives grant/research support from Amgen and Merck. A. Lievre received grant/research support from Merck.
Rights and permissions
About this article
Cite this article
Lièvre, A., Laurent-Puig, P. Predictive value of KRAS mutations in chemoresistant CRC. Nat Rev Clin Oncol 6, 306–307 (2009). https://doi.org/10.1038/nrclinonc.2009.69
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.69
This article is cited by
-
Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significance
Nature Communications (2023)
-
Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique
Diagnostic Pathology (2015)
-
Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
BMC Cancer (2013)
